According to European Dermatology Forum guidelines, systemic treatment with the biologic agents adalimumab or infliximab is reserved for patients with treatment-resistant, moderate to severe hidradenitis suppurativa (moderate Hurley II or Hurley III stage). These agents should be used only after lack of response to other agents such as clindamycin, rifampin, doxycycline, and acitretin. Etanercept should not be used in patients with moderate to severe hidradenitis suppurativa that is unresponsive to conventional systemic therapy.
Pain management should be offered as needed, and general measures to improve quality of life, such as smoking cessation, weight loss, and help with bandaging lesions, should be offered to all patients with hidradenitis suppurativa.
Learn more about treatment guidelines for chronic hidradenitis suppurativa.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
Editor's Recommendations
Medscape © 2019 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: William D. James. Fast Five Quiz: Hidradenitis Suppurativa Management - Medscape - Nov 05, 2019.
Comments